Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics and Pharmacodynamics of LY2963016 Compared to Lantus in Healthy Subjects Following Two Single Subcutaneous Doses

Next Previous
X
Search
Trial Profile

Pharmacokinetics and Pharmacodynamics of LY2963016 Compared to Lantus in Healthy Subjects Following Two Single Subcutaneous Doses

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 13 Jun 2014 Primary endpoint of maximum Serum LY2963016 or Lantus Concentration (Cmax) has not been met according to results presented at the 74th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2014 Primary endpoint of Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-) has been met, according to results presented at the 74th Annual Scientific Sessions of the American Diabetes Association.
    • 28 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top